The patents will allow Mydecine to scale its drug development program after promising discoveries in the field of MDMA research

() (OTCMKTS:MYOCF) () is widening its psychedelics portfolio to include MDMA-like compounds. 

The Denver-based psychedelics company said it had filed a patent to cover the new compounds, allowing it to scale its drug development program after promising discoveries in the field of MDMA research. 

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to MDMA to treat post-traumatic stress disorder (PTSD). 

READ: Mydecine launching Mindleap 2.0, an online community for psychedelic education and support

With its new patent covering entactogenic compounds, Mydecine would be able to develop treatments that “precisely” match the needs of medical…



Read Full Article Here